LEGN - Johnson & Johnson powers to Q3 beat as pharma outperforms
2023-10-17 07:11:38 ET
More on Johnson & Johnson
- Johnson & Johnson: A Conservative High-Yield Dividend Aristocrat Buy
- Johnson & Johnson Q3 Earnings Preview: Don't Count On Different Proposition Post Kenvue Spin-Out
- Johnson & Johnson: The Bull Case Can No Longer Be Ignored
- Johnson & Johnson Non-GAAP EPS of $2.66 beats by $0.14, revenue of $21.35B beats by $300M
- Johnson & Johnson's Q3 results set to be first report after separation of Kenvue
For further details see:
Johnson & Johnson powers to Q3 beat as pharma outperforms